When building your watch list, look for stocks with an 80 or higher RS Rating. Intellia Therapeutics is one stock that just reached the mark, now earning a score of 80.
Risk Management In The Stock Market: How Much Money To Invest Now
IBD's proprietary rating measures market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the last 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the top-performing stocks tend to have an RS Rating north of 80 as they begin their biggest climbs.
While it's not currently an ideal time to jump in, see if the stock is able to offer and clear an appropriate buy point.
Intellia Therapeutics posted 0% EPS growth in its most recent report. Revenue gains came in at -43%. The company is expected to report its latest results on or around Jul. 31.
Intellia Therapeutics earns the No. 224 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Harmony Biosciences and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
